Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology on the Use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in Preclinical Models of Autoimmune Disease

Published: Oct 23, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. announces oral presentations at the 2013 ACR Annual Meeting on the use of its oral SINE XPO1 antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). Preclinical evidence suggests that XPO1 antagonists lead to the nuclear accumulation of I-kB, the inhibitor of the pro-inflammatory protein nuclear factor kB (NF-kB). This leads to inhibition of NF-kB activity, which could reduce inflammation.

Help employers find you! Check out all the jobs and post your resume.

Back to news